[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649208":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":30,"collaborators":26,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":26,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":26,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":26},{"fullName":5,"class":6},"Prana Therapies Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active PRA-216","ACTIVE_COMPARATOR","Participants with moderate to severe COPD will be randomized to receive PRA-216",[13],"Drug: PRA-216",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants with moderate to severe COPD will be randomized to receive placebo",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","PRA-216","biologic",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"matching placebo for PRA-216",[15],{"type":31,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100649208","phase-2-pra-216-copd-safety-and-biomarker-study-100649208",false,"NCT07730281","PRA-216 COPD Safety and Biomarker Study","A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation","Inclusion Criteria:\n\n* Age 40-80\n* Willing and able to attend all study visits, comply with study requirements.\n* Able and willing to provide written informed consent\n* Documented COPD diagnosis prior for at least 12 months prior to screening.\n* Currently receiving maintenance COPD medications at a stable dose for at least 2 months prior to visit 1\n\nExclusion Criteria:\n\n* Evidence of clinically significant pulmonary condition or disease other than COPD\n* Any physical or psychological condition that prohibits study completion\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Receipt of immunosuppressant therapies for asthma within 3 months of screening\n* Major surgery occurring within 8 weeks months prior to first dose of investigational product.\n* Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.","ALL","40 Years","80 Years",{"count":43,"type":44},40,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).",[50],"Chronic Obstructive Pulmonary Disease (COPD)",[52,53,54],"Inflammatory response","pharmacokinetics","pharmacodynamics","NOT_YET_RECRUITING","2026-07-23",{"date":58,"type":59},"2026-07-28","ACTUAL",{"date":61,"type":44},"2026-08-01",{"date":63,"type":44},"2027-09-01",{"name":5,"class":6}]